Utilization of Evidence Blueprint Initiative to Transform Capability Development in AstraZeneca Spain.

Area of Science:

• Pharmaceutical industry
• Health economics and outcomes research
• Real-world evidence generation

Background:

• The role of Medical Affairs (MA) has evolved from traditional evidence dissemination to integrating real-world data (RWD) and diverse data sources.
• AstraZeneca (AZ) Spain identified the need to assess and improve its evidence-generation capabilities to align with global and local priorities.

Purpose of the Study:

• To systematically assess AZ Spain's current evidence-generation capabilities using the Evidence Blueprint framework.
• To identify specific gaps and develop targeted strategies for enhancing evidence generation.

Main Methods:

• A systematic self-assessment was conducted across ten core areas using the Evidence Blueprint.
• A four-phase approach was employed: defining capabilities, assessing maturity, developing a roadmap, and implementing changes.

Main Results:

• Five priority areas for improvement were identified, including Innovative Value Strategies/Payer Evidence and RWD Vision and Strategy.
• Key actions included developing processes for outcome-based agreements, mapping databases for RWD, creating cross-functional evidence planning, establishing research partnerships, and adopting patient-centric methodologies.

Conclusions:

• The Evidence Blueprint framework effectively identified gaps and guided improvements in evidence-generation capabilities at AZ Spain.
• Initiatives aligned with AZ's MA 2030 vision drive innovation, enhance decision-making, and contribute to the healthcare ecosystem.